With the help of our highly experienced staff, Creative Biolabs is dedicated to timely, high-quality dopamine transporter antagonist services for our customers worldwide. Our expertise in the field of psychotropic drug development can give you a detailed insight into your biologic, helping to accelerate your drug development process.
Dopamine Transporter (DAT) Antagonist with Psychiatric Disorders
Dopaminergic homeostasis is maintained by the DAT, a transmembrane transporter containing 12 putative transmembrane domains, which functions to take up released dopamine (DA) from the synaptic cleft. DAT plays a crucial role in controlling DA-mediated neurotransmission and a number of associated behaviors. Furthermore, DAT abnormalities have been implicated in schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder (ADHD). This opened the door to the development of antipsychotic drugs with dopamine antagonist activity that acts through dopamine system stabilization.
Modafinil shares properties with other compounds now recognized as atypical DAT inhibitors. Along with recently developed atypical DA releasers, it renews interest in the DAT as a pharmacotherapeutic target for treating stimulant use disorders.
Orphanin FQ is an endogenous antagonist of DAT, and it affects locomotion and other activities at least partly by inhibiting DAT and directly affecting DA transmission or by inhibiting GABA transporter from changing DA transmission indirectly.
The atypical antipsychotics also contain clozapine and quetiapine. Furthermore, bupropion with its metabolites inhibited reuptake at human transporters for both DA and norepinephrine, with slightly greater functional potency at the DAT than at the nor-epinephrine transporter.
Recently, the DAT becomes an early preclinical focus for discovering treatment compounds. Additionally, atypical antipsychotics are effective treatments of schizophrenia and manic symptoms, presumably in part by antagonizing DAT. The DAT antagonist plays an important role in neurotoxicity and a number of psychiatric disorders, including schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder, drug abuse, and ADHD. Typical DAT blockers, at high enough concentrations or doses, are expected to (i) fully inhibit DA uptake; (ii) fully inhibit the binding of another blocker and the release of the substrate by reversed transport. Examples of typical DAT blockers or releasers are cocaine or amphetamine, respectively. The atypical DAT inhibitors also have potential as treatments for stimulant abuse, and they may provide important basic information about DAT function. Moreover, there may as well be additional clinical uses for these compounds in the treatment of ADHD and obesity.
DAT Antagonist Development at Creative Biolabs
DAT has been implicated in numerous neuropsychiatric disorders such as schizophrenia and bipolar disorder. As a leading drug development company, Creative Biolabs has armed itself with a powerful and standardized psychotropic drug development platform, aiming to offer the best and most convenient target-related development services. We have made a long-term commitment to the discovery and development of therapeutic drugs for psychiatric disorders. Our scientists currently help develop and ultimately provide custom protocols based on specific client needs for either DAT antagonist.
Creative Biolabs is a global provider to develop targets of psychiatric disorders by using our functional tools. Our seasoned scientific team has developed an advanced platform to comprehensively develop DAT antagonists to bring our customers impeccable psychotropic drug development services. To get more information, a quote, or to schedule a teleconference, please contact us.
For Research Use Only.
